Biotechnology News

DURHAM, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet...

WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to...

CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and...

Checkerspot today introduced Algolein™ a new line of precision-fermented algal ingredients for the personal care and cosmetics industry.

2025 ANNUAL RESULTS Annual revenue up 9% to €168 millionRoll-out of the Group’s strategy: Sales of proprietary products up 20%, accounting for 35% of revenueInternationalisation: 42% of revenue...

RESULTAT ANNUEL 2025 Progression du chiffre d’affaires annuel de 9% à 168 M€Déploiement de la stratégie du Groupe : Ventes des produits propriétaires en hausse de 20%, à 35% du Chiffre...

NETANYA, Israel and REHOVOT, Israel, April 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (the “Company”) today announced that it has completed the acquisition of 100% of Zorronet...

Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout anticipated Q1 2027Alzheimer’s disease Phase 3 trial 75% enrolledParkinson's disease open-label study 28%...

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

EMPAVELIMD (pegcétacoplan) est le premier traitement autorisé dans le traitement des patients adultes et pédiatriques de 12 ans et plus atteints de glomérulopathie à dépôts de C3 (GC3) ou de...